Revenue per share:2018 - $0.0702023 - $0.033A more than 50% decline in revenue per share (and even worse if you include options...)MD's remuneration (cumulative): > $1,500,000How does anyone still defend this truly inept performance?
RNU Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some
I88 Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”
TLX Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug
